Crestor Star Continues To Rise, And Trajectory Looks Good
This article was originally published in The Pink Sheet Daily
Executive Summary
2009 should be a big year for the Crestor franchise, with filings based on the JUPITER trial and a fixed-dose combination with Abbott’s Trilipix.
You may also be interested in...
JUPITER Shines Celestial Glow On Statin Use; Docs Ready, But Are Payers?
A few months after the release of AstraZeneca's widely heralded JUPITER Crestor study, physicians seem prepared to prescribe statins more broadly based on that evidence, according to discussion at the American College of Cardiology annual meeting
JUPITER Shines Celestial Glow On Statin Use; Docs Ready, But Are Payers?
A few months after the release of AstraZeneca's widely heralded JUPITER Crestor study, physicians seem prepared to prescribe statins more broadly based on that evidence, according to discussion at the American College of Cardiology annual meeting
Clinical And Economic Implications Of Crestor JUPITER Study Headline ACC Meeting
Planet-struck American College of Cardiology kicks off its annual scientific session with a focus on the impact of AstraZeneca’s high-profile rosuvastatin study for medical practice and for the economics of cardiac health care.